The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Thrombosis Prophylaxis in Cancer Patients

Risk-stratified prevention of venous thromboembolism in oncology

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Thrombosis Prophylaxis in Cancer Patients?

Cancer-associated thrombosis is a major cause of morbidity and mortality. Risk varies by tumor type (high in pancreatic, gastric, primary brain, lung, gynecologic), stage, treatment, and patient factors. Risk assessment tools (Khorana score) help identify high-risk ambulatory patients.

Prophylaxis is recommended for hospitalized cancer patients without contraindications, with low-molecular-weight heparin (LMWH) preferred over unfractionated heparin in most cases. Direct oral anticoagulants (apixaban, rivaroxaban) are increasingly used in select hospitalized and ambulatory settings.

Ambulatory chemotherapy prophylaxis is considered for high-risk patients (Khorana score 2 or higher) using DOACs or LMWH, weighing bleeding risk. Mechanical prophylaxis (intermittent pneumatic compression) supplements pharmacologic methods when bleeding risk is high.

Symptoms

Used to prevent thrombosis, not for treatment
Routine in most cancer hospitalizations
Selected use in high-risk ambulatory patients
Mechanical alternatives for bleeding risk
Side effects include bleeding and heparin-induced thrombocytopenia

Risk Factors

High-risk tumor sites and advanced disease
Recent surgery, chemotherapy, anti-angiogenic agents
Indwelling central venous catheters
Immobility and hospitalization
Personal or family history of thrombosis

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • On hospital admission for cancer or treatment
  • Before starting high-risk chemotherapy
  • When new VTE-related symptoms appear
  • When bleeding occurs on prophylaxis
  • For risk reassessment during treatment

Treatment Methods

01
Risk assessment with Khorana or similar scores
02
LMWH for hospitalized patients without contraindication
03
DOACs (apixaban, rivaroxaban) in selected cases
04
Ambulatory prophylaxis for Khorana 2 or higher
05
Mechanical prophylaxis when bleeding risk is high
06
Catheter-related VTE prevention strategies
07
Multidisciplinary review for individualized risk-benefit

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.